Physician profile
Anilkumar Patel
NPI 1902995319
$4,399.01
in general payments reported to CMS, 2019-2025
34 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $682 · 2020: $379 · 2021: $641 · 2022: $557 · 2023: $847 · 2024: $821 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,139.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $746.67 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $559.55 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $472.23 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $313.67 | 2020-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $254.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $252.64 | 2019-2024 | Trelegy Ellipta |
| Amgen INC. | $201.36 | 2021-2024 | Repatha, Otezla, Evenity |
| Ironwood Pharmaceuticals, INC | $188.86 | 2019-2024 | Linzess |
| Abbvie INC. | $129.93 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $109.39 | 2023 | Gemtesa |
| Merck Sharp & Dohme LLC | $106.12 | 2019-2022 | |
| Mylan Specialty L.P. | $98.03 | 2020-2022 | |
| Abbott Laboratories | $95.07 | 2019-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $85.65 | 2019-2021 | |
| Baxter Healthcare | $71.04 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $70.87 | 2022 | |
| Amarin Pharma, INC. | $68.62 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $65.64 | 2019-2020 | |
| Allergan, INC. | $64.92 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $52.82 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $41.12 | 2019-2024 | Ingrezza |
| Dexcom, INC. | $38.75 | 2022-2023 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $37.58 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $36.12 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $35.82 | 2019 | |
| Sanofi Pasteur INC. | $30.44 | 2025 | |
| Smith+Nephew, INC. | $30.27 | 2024 | Collagenase Santyl |
| Novartis Pharmaceuticals Corporation | $27.39 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $22.97 | 2020 | |
| Medline Industries LP | $20.69 | 2024 | |
| Irhythm Technologies, INC. | $18.50 | 2019 | |
| Qiagen, LLC | $18.45 | 2024 | |
| Arbor Pharmaceuticals, INC. | $17.08 | 2021 | |
| Abiomed | $16.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anilkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.